<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411151</url>
  </required_header>
  <id_info>
    <org_study_id>GC-SU-2006</org_study_id>
    <secondary_id>KKS 2005-015</secondary_id>
    <nct_id>NCT00411151</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer</brief_title>
  <official_title>An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be conducted to evaluate the efficacy, safety, and tolerability of sunitinib
      (sunitinib-malate) as a second-line palliative therapy in metastatic gastric cancer. Despite
      the efforts in front-line therapy, second-line protocols have not yet been established in
      randomized clinical trials for those patients. Although many patients are still in good
      performance status and present with low tumor burden after failure of first-line
      chemotherapy, they may clearly benefit from second-line treatment. Increasingly more
      metachronic metastatic patients are urging for new platinum-free therapeutic options due to
      the fast-growing use of (neo-) adjuvant platin-based protocols.

      So far, only sparse data on chemotherapy are available after failure of platin-based
      protocols. Nearly only irinotecan-containing combinations have properly been analyzed, and
      produced excellent response rates and survival times of up to 30% and 7.6 months,
      respectively. However, irinotecan has not been approved yet for this indication. In addition,
      as irinotecan-containing regimens have been submitted for approval for first-line therapy,
      second-line regimens in irinotecan-refractory patients have not been evaluated in any trial.
      Thus, there is an urgent need to establish new second-line treatment options for both,
      cisplatinum- or irinotecan-combination refractory patients with advanced or metastatic
      gastric cancer.

      Sunitinib inhibits the receptor tyrosine kinases (RTKs) involved in tumor proliferation and
      angiogenesis, specifically the VEGFR, PDGFR, KIT, FLT-3, and RET. The VEGF pathway has been
      shown to be a significant factor in metastatic gastric cancer. In gastric carcinoma cells,
      VEGF ligands and its receptors are definitely involved in the process of tumor progression.
      KDR and FLT-1 are expressed widely and VEGF stimulated KDR-positive tumor cell growth
      directly. The ligand VEGF-C has also been shown to be involved in progression of human
      gastric carcinoma, particularly via lymphangiogenesis. In addition, peritoneal metastases of
      some cancers such as gastric cancers were largely dependent on VEGF. Therefore, patients with
      chemo-refractory metastatic gastric cancer might benefit from VEGFR inhibitory therapy with
      sunitinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>one year</time_frame>
    <description>The primary endpoint is the ORR within the first 6 treatment cycles, defined as the percentage of participants with a confirmed reduction in tumor size fulfilling the criteria for complete or partial response (CR or PR) according to RECIST. CR=disappearance of all target lesions, PR=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>one year</time_frame>
    <description>PFS is defined as the time from first dose of trial medication to first documentation of objective tumor progression or to death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>one year</time_frame>
    <description>OS is defined as the time from the first dose of trial medication to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-Year Survival</measure>
    <time_frame>one year</time_frame>
    <description>One-year survival is defined as the percentage of participants surviving for at least one year after first dose of trial medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>one year</time_frame>
    <description>The number of participants with at least one adverse event was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Serious Adverse Events</measure>
    <time_frame>one year</time_frame>
    <description>The number of participants with at least one Serious Adverse Event was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Adverse Events in ≥10% of Patients</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Barrett Esophagus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib-Malate</intervention_name>
    <description>Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent of the patient before the start of specific protocol
             procedures

          -  Histologically proven adenocarcinoma of stomach, esophagogastric junction or lower
             esophagus (Barrett carcinoma)

          -  Measurable metastatic disease according to the Response Evaluation Criteria in Solid
             Tumors (RECIST). If locally recurrent disease, it must be associated with at least one
             measurable lymph node (&gt; 20 mm by computed tomography [CT] scan or &gt; 10 mm with spiral
             CT).

          -  Failure of prior palliative chemotherapy/chemotherapies (at least one irinotecan- or
             cisplatin-based). Failure is defined either by progression of disease or by
             significant toxicity that precludes further treatment.

          -  At least 3 weeks from previous chemotherapy at first dose of trial drug

          -  Resolution of all acute toxic side effects of prior therapy or surgical procedures to
             grade ≤ 1 National Cancer Institute-Common Toxicity Criteria (NCI-CTC) (except for the
             laboratory values)

          -  Adequate organ function as defined by the following criteria:

               -  Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase
                  [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase
                  [SGPT]) ≤ 2.5 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver
                  function abnormalities are due to underlying malignancy

               -  Total serum bilirubin ≤ 1.5 x ULN

               -  Absolute neutrophil count (ANC) ≥1500/microL

               -  Platelets ≥ 100,000/microL

               -  Hemoglobin ≥ 8.0 g/dL without support of growth factors (previous administration
                  of erythrocyte concentrate is allowed)

               -  Serum calcium ≤ 12.0 mg/dL

               -  Serum creatinine ≤ 2.0 x ULN

               -  Lipase/amylase ≤ 2.5 x ULN

               -  All other laboratory values specified in the protocol (white blood cell count,
                  white blood cell differential, alkaline phosphatase, sodium, potassium,
                  creatinine clearance): resolution of all side effects of prior therapy or
                  surgical procedure to grade &lt; 3 NCI-CTC

          -  At least 4 weeks from any major surgery (at first dose of trial drug)

          -  Karnofsky Performance Status (KPS) ≥ 70

          -  Life expectancy &gt; 12 weeks

          -  Patients must be able to swallow sunitinib capsules

          -  Patients who understand the nature of the trial and are willing and able to comply
             with scheduled visits, treatment plans, laboratory tests and other trial procedures

          -  Female patients who are capable of bearing children must have a negative pregnancy
             test result (serum or urine) at trial entry. All women included in the trial must be
             surgically sterile or postmenopausal or agree to employ adequate birth control
             measures for the duration of the trial and six months post-dosing. Male patients must
             be surgically sterile or must agree to use effective contraception during the trial
             and six months post-dosing.

        Exclusion Criteria:

          -  Tumor type other than adenocarcinoma (e.g., leiomyosarcoma, lymphoma) or a second
             cancer except in patients with squamous or basal cell carcinoma of the skin or
             carcinoma in situ of the cervix which has been effectively treated. Patients
             curatively treated and disease free for at least 5 years will be discussed with the
             sponsor before inclusion.

          -  Patients with known brain or leptomeningeal metastasis

          -  Intake of non-permitted concomitant drugs. (The coordinating investigator should be
             contacted to discuss the individual case.)

               -  Concomitant treatment with antiarrhythmics and drugs with dysrhythmic potential
                  (i.e., terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol,
                  bepridil, haloperidol, risperidone, and indapamide)

               -  Administration of potent CYP34A inhibitors during or within 7 days before start
                  of sunitinib-treatment (e.g. ketoconazole, itraconazole, clarithromycin,
                  erythromycin, diltiazem, verapamil, delavirdine, indinavir, saquinavir,
                  ritonavir, atazanavir, nelfinavir, grapefruit juice)

               -  Administration of potent CYP3A4 inducers during or within 12 days before start of
                  sunitinib-treatment (e.g. dexamethasone, rifampicin, rifabutin, carbamazepine,
                  phenobarbital, phenytoin, St. John´s wort, efavirenz, tipranavir)

               -  Ongoing treatment with therapeutic doses of anticoagulants such as Coumadin or
                  heparins. (However, low dose Coumadin up to 2 mg by mouth [PO] daily for deep
                  vein thrombosis prophylaxis is allowed.)

               -  Any other medicinal anticancer therapy during treatment phase except treatment
                  with non-conventional therapies (e.g. herbs or acupuncture) and vitamins/mineral
                  supplements, provided that they do not interfere with the trial endpoint, in the
                  opinion of the investigator

               -  Concurrent systemic immune therapy, chemo- or hormone therapy

               -  Concomitant or within a 4-week period administration (from first dose of trial
                  drug) of any other experimental drug under investigation (except for irinotecan
                  and cetuximab) and participation in another clinical trial

          -  Any prior radiotherapy of target lesions

          -  Bowel obstruction, history or presence of inflammatory enteropathy or extensive
             intestinal resection (&gt; hemicolectomy or extensive small intestine resection with
             chronic diarrhea), Crohn's disease, ulcerative colitis

          -  Current history of chronic diarrhoea

          -  Active disseminated intravascular coagulation, or patients prone to thromboembolism

          -  Any of the following events (in any grade) prior to starting the trial treatment:

               -  myocardial infarction

               -  severe/unstable angina

               -  coronary/peripheral artery bypass graft

               -  congestive heart failure

               -  cerebrovascular accident or transient ischemic attack

               -  pulmonary embolism

          -  Known history of QT interval prolongation, ongoing QT prolongation (&gt; 450 msec for
             males or &gt; 470 msec for females), any cardiac ventricular dysrhythmias, atrial
             fibrillation of any grade

          -  Hypertension that cannot be controlled by medications (&gt; 150/100 mmHg despite optimal
             medical therapy)

          -  Known human immunodeficiency virus (HIV) infection

          -  Active uncontrolled infection

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with trial participation or trial drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into the
             trial

          -  Pregnant or lactating women

          -  Known allergic/hypersensitivity reaction to any of the components of the treatment; or
             known drug abuse/alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Moehler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes-Gutenberg-University of Mainz, I. Dept. Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universität Heidelberg, Nationales Zentrum für Tumorerkrankungen</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Würtemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Würtemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU München, Klinikum rechts der Isar, II. Med. Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der GHS Essen, Innere Klinik und Poliklinik, Tumorforschung</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik zu Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus, Med. Klinik I</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH Nordwest, Abteilung für Hämatologie und Onkologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2006</study_first_posted>
  <results_first_submitted>November 29, 2010</results_first_submitted>
  <results_first_submitted_qc>December 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2011</results_first_posted>
  <last_update_submitted>January 19, 2011</last_update_submitted>
  <last_update_submitted_qc>January 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Markus Moehler, MD</name_title>
    <organization>Johannes Gutenberg University Mainz</organization>
  </responsible_party>
  <keyword>Adenocarcinoma of esophagogastric junction</keyword>
  <keyword>Adenocarcinoma of lower esophagus (Barrett carcinoma)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient in (FPI): 15.02.2007 Last patient out (LPO): 20.08.2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib</title>
          <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial prematurely closed</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib</title>
          <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="12.07" lower_limit="28" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status (KPS)</title>
          <description>KPS is the Karnofsky Lansky Score. Higher values in the KPS represent a better physical condition. 100%=normal, 90%=able to carry on normal activity, 80%=normal activity with effort, 70%=cares for self but unable to carry on normal activity, 60%=requires occasional assistance, 50%=requires considerable assistance and frequent medical care, 40%=disabled, requires special care and assistance, 30%=severely disabled and hospitalization indicated but death not imminent, 20%=very sick and requires hospitalization, 10%=moribund and fatal processes progressing rapidly, 0%=dead</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Localisation of adenocarcinoma</title>
          <description>Note that multiple answers are permitted.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stomach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroesophageal junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower esophagus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Grading of adenocarcinoma</title>
          <description>Grading of adenocarcinoma is the tumor grading according to UICC.
1 (low grade)=well differentiated, 2 (intermediate grade)=differentiated, 3 (high grade)=poorly differentiated, 4 (high grade)=undifferentiated</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Localisation of target lesions</title>
          <description>Note that multiple answers are permitted.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Primary tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node truncus coeliacus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node mediastinum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node spleen/pancreas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node paraaortal caudal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritoneum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Soft tissue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total size of target lesions</title>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="10" upper_limit="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Localisation of non-target lesions</title>
          <description>Note that multiple answers are permitted.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Primary tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node truncus coeliacus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node mediastinum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph node paraaortal caudal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritoneum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No non-target lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>The primary endpoint is the ORR within the first 6 treatment cycles, defined as the percentage of participants with a confirmed reduction in tumor size fulfilling the criteria for complete or partial response (CR or PR) according to RECIST. CR=disappearance of all target lesions, PR=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions</description>
        <time_frame>one year</time_frame>
        <population>Intention-to-treat (ITT) population comprises all patients registered, except one patient whose tumor diagnosis was not confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>The primary endpoint is the ORR within the first 6 treatment cycles, defined as the percentage of participants with a confirmed reduction in tumor size fulfilling the criteria for complete or partial response (CR or PR) according to RECIST. CR=disappearance of all target lesions, PR=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions</description>
          <population>Intention-to-treat (ITT) population comprises all patients registered, except one patient whose tumor diagnosis was not confirmed.</population>
          <units>Participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="0.48" upper_limit="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS is defined as the time from first dose of trial medication to first documentation of objective tumor progression or to death due to any cause, whichever occurs first.</description>
        <time_frame>one year</time_frame>
        <population>Intention-to-treat (ITT) population comprises all patients registered, except one patient whose tumor diagnosis was not confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>PFS is defined as the time from first dose of trial medication to first documentation of objective tumor progression or to death due to any cause, whichever occurs first.</description>
          <population>Intention-to-treat (ITT) population comprises all patients registered, except one patient whose tumor diagnosis was not confirmed.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="36" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as the time from the first dose of trial medication to date of death due to any cause.</description>
        <time_frame>one year</time_frame>
        <population>Intention-to-treat (ITT) population comprises all patients registered, except one patient whose tumor diagnosis was not confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is defined as the time from the first dose of trial medication to date of death due to any cause.</description>
          <population>Intention-to-treat (ITT) population comprises all patients registered, except one patient whose tumor diagnosis was not confirmed.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177" lower_limit="106" upper_limit="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One-Year Survival</title>
        <description>One-year survival is defined as the percentage of participants surviving for at least one year after first dose of trial medication.</description>
        <time_frame>one year</time_frame>
        <population>Intention-to-treat (ITT) population comprises all patients registered, except one patient whose tumor diagnosis was not confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
          </group>
        </group_list>
        <measure>
          <title>One-Year Survival</title>
          <description>One-year survival is defined as the percentage of participants surviving for at least one year after first dose of trial medication.</description>
          <population>Intention-to-treat (ITT) population comprises all patients registered, except one patient whose tumor diagnosis was not confirmed.</population>
          <units>Participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="12.8" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>The number of participants with at least one adverse event was measured.</description>
        <time_frame>one year</time_frame>
        <population>Safety population comprises all patients registered.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>The number of participants with at least one adverse event was measured.</description>
          <population>Safety population comprises all patients registered.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability: Serious Adverse Events</title>
        <description>The number of participants with at least one Serious Adverse Event was measured.</description>
        <time_frame>one year</time_frame>
        <population>Safety population comprises all patients registered.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability: Serious Adverse Events</title>
          <description>The number of participants with at least one Serious Adverse Event was measured.</description>
          <population>Safety population comprises all patients registered.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability: Adverse Events in ≥10% of Patients</title>
        <time_frame>one year</time_frame>
        <population>Safety population comprises all patients registered.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability: Adverse Events in ≥10% of Patients</title>
          <population>Safety population comprises all patients registered.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucosal inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysgeusia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paraesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palmar-plantar erythrodysaesthesia syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib</title>
          <description>open-label and uncontrolled treatment cycle &quot;4+2&quot;: Sunitinib capsules for oral administration (50mg daily for 4 weeks and 2 weeks rest)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>M. Kabisch</name_or_title>
      <organization>Interdisciplinary Center for Clinical Trials (IZKS Mainz)</organization>
      <phone>++49 (0)6131-179922</phone>
      <email>kabisch@izks-mainz.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

